Tomasz (Tom) Beer

Professor

  • 14418 Citations
  • 53 h-Index
1976 …2019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 2000 2019

2019

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)

Kapoor, R., Deek, M. P., McIntyre, R., Raman, N., Kummerlowe, M., Chen, I., Gaver, M., Wang, H., Denmeade, S., Lotan, T., Paller, C., Markowski, M., Carducci, M., Eisenberger, M., Beer, T. T., Song, D. Y., Deweese, T. L., Hearn, J. W., Greco, S., Deville, C. & 7 others, Desai, N. B., Heath, E. I., Liauw, S., Spratt, D. E., Hung, A., Antonarakis, E. S. & Tran, P. T., Jun 13 2019, In : BMC cancer. 19, 1, 572.

Research output: Contribution to journalArticle

Open Access
Salvage Therapy
Prostatectomy
Double-Blind Method
Prostatic Neoplasms
Radiotherapy

Combining options in metastatic prostate cancer

Kopp, R. & Beer, T. T., Jan 1 2019, In : Nature Reviews Urology.

Research output: Contribution to journalComment/debate

Prostatic Neoplasms
docetaxel
Therapeutics

Correction: Epigenetic therapy with panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer (Clinical Cancer Research (2019) 25 (52-63) DOI: 10.1158/1078-0432.CCR-18-1589)

Ferrari, A. C., Alumkal, J., Stein, M. N., Taplin, M. E., Babb, J., Barnett, E. S., Gomez-Pinillos, A., Liu, X., Moore, D., DiPaola, R. & Beer, T. T., Apr 15 2019, In : Clinical Cancer Research. 25, 8, 1 p.

Research output: Contribution to journalComment/debate

Open Access
Castration
Epigenomics
Prostatic Neoplasms
Emotions
Research
5 Citations (Scopus)

Epigenetic therapy with panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer

Ferrari, A. C., Alumkal, J., Stein, M. N., Taplin, M. E., Babb, J., Barnett, E. S., Gomez-Pinillos, A., Liu, X., Moore, D., DiPaola, R. & Beer, T. T., Jan 1 2019, In : Clinical Cancer Research. 25, 1, p. 52-63 12 p.

Research output: Contribution to journalArticle

Castration
Epigenomics
Prostatic Neoplasms
Arm
Androgen Receptors

Erratum to: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy (Nature Communications, (2018), 9, 1, (4972), 10.1038/s41467-018-07411-7)

Geng, H., Xue, C., Mendonca, J., Sun, X-X., Liu, Q., Reardon, P. N., Chen, Y., Qian, K., Hua, V., Chen, A., Pan, F., Yuan, J., Dang, S., Beer, T. T., Dai, M., Kachhap, S. K. & Qian, Z. D., Dec 1 2019, In : Nature Communications. 10, 1, 164.

Research output: Contribution to journalComment/debate

hypoxia
Androgens
therapy
switches
communication
5 Citations (Scopus)

Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer

Chen, W. S., Aggarwal, R., Zhang, L., Zhao, S. G., Thomas, G., Beer, T. T., Quigley, D. A., Foye, A., Playdle, D., Huang, J., Lloyd, P., Lu, E., Sun, D., Guan, X., Rettig, M., Gleave, M., Evans, C. P., Youngren, J., True, L., Lara, P. & 8 others, Kothari, V., Xia, Z., Chi, K. N., Reiter, R. E., Maher, C. A., Feng, F. Y., Small, E. J. & Alumkal, J., Jan 1 2019, In : European Urology.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Catenins
Survival Analysis
Survival
1 Citation (Scopus)
Genetic Testing
Prostatic Neoplasms
Clinical Trials
Genetic Counseling
Neoplasms
2 Citations (Scopus)

MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer

Nickols, N. G., Nazarian, R., Zhao, S. G., Tan, V., Uzunangelov, V., Xia, Z., Baertsch, R., Neeman, E., Gao, A. C., Thomas, G., Howard, L., De Hoedt, A. M., Stuart, J., Goldstein, T., Chi, K., Gleave, M. E., Graff, J., Beer, T. T., Drake, J. M., Evans, C. P. & 11 others, Aggarwal, R., Foye, A., Feng, F. Y., Small, E. J., Aronson, W. J., Freedland, S. J., Witte, O. N., Huang, J., Alumkal, J., Reiter, R. E. & Rettig, M. B., Jan 1 2019, In : Prostate Cancer and Prostatic Diseases.

Research output: Contribution to journalArticle

Open Access
Castration
Mitogen-Activated Protein Kinase Kinases
Prostatic Neoplasms
Therapeutics
Phosphotransferases

Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial

Armstrong, A. J., Lin, P., Higano, C. S., Iversen, P., Sternberg, C. N., Tombal, B., Phung, D., Parli, T., Krivoshik, A. & Beer, T. M., Nov 1 2019, In : European urology oncology. 2, 6, p. 677-684 8 p.

Research output: Contribution to journalArticle

Open Access
Castration
Prostate-Specific Antigen
Prostatic Neoplasms
Randomized Controlled Trials
Therapeutics
2 Citations (Scopus)

Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity

Aggarwal, R. R., Quigley, D. A., Huang, J., Zhang, L., Beer, T. T., Rettig, M. B., Reiter, R. E., Gleave, M. E., Thomas, G., Foye, A., Playdle, D., Lloyd, P., Chi, K. N., Evans, C. P., Lara, P. N., Feng, F. Y., Alumkal, J. & Small, E. J., Jun 1 2019, In : Molecular cancer research : MCR. 17, 6, p. 1235-1240 6 p.

Research output: Contribution to journalArticle

Neuroendocrine Carcinoma
Neuroendocrine Cells
Small Cell Carcinoma
Prostatic Neoplasms
Genome
2018
56 Citations (Scopus)

Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: A multi-institutional prospective study

Aggarwal, R., Huang, J., Alumkal, J., Zhang, L., Feng, F. Y., Thomas, G., Weinstein, A. S., Friedl, V., Zhang, C., Witte, O. N., Lloyd, P., Gleave, M., Evans, C. P., Youngren, J., Beer, T. T., Rettig, M., Wong, C. K., True, L., Foye, A., Playdle, D. & 11 others, Ryan, C. J., Lara, P., Chi, K. N., Uzunangelov, V., Sokolov, A., Newton, Y., Beltran, H., Demichelis, F., Rubin, M. A., Stuart, J. M. & Small, E. J., Aug 20 2018, In : Journal of Clinical Oncology. 36, 24, p. 2492-2503 12 p.

Research output: Contribution to journalArticle

Neuroendocrine Cells
Prostatic Neoplasms
Prospective Studies
Castration
Therapeutics
5 Citations (Scopus)

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer

Armstrong, A. J., Lin, P., Higano, C. S., Sternberg, C. N., Sonpavde, G., Tombal, B., Templeton, A. J., Fizazi, K., Phung, D., Wong, E. K., Krivoshik, A. & Beer, T. T., Nov 1 2018, In : Annals of oncology : official journal of the European Society for Medical Oncology. 29, 11, p. 2200-2207 8 p.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Drug Therapy
Survival
Patient Care
2 Citations (Scopus)

DNA repair gene alterations and PARP inhibitor response in patients with metastatic castration-resistant prostate cancer

Lu, E., Thomas, G., Chen, Y., Wyatt, A. W., Lloyd, P., Youngren, J., Quigley, D., Bergan, R., Bailey, S., Beer, T. T., Feng, F. Y., Small, E. J. & Alumkal, J., Aug 1 2018, In : JNCCN Journal of the National Comprehensive Cancer Network. 16, 8, p. 933-937 5 p.

Research output: Contribution to journalArticle

Castration
DNA Repair
Prostatic Neoplasms
Genes
BRCA2 Gene
6 Citations (Scopus)

Erratum: Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (Cell (2018) 174(3) (758–769.e9), (S0092867418308420) (10.1016/j.cell.2018.06.039))

Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., Playdle, D., Barnard, T. J., Zhang, L., Zhang, J., Youngren, J. F., Cieslik, M. P., Parolia, A., Beer, T. T., Thomas, G., Chi, K. N. & 43 others, Gleave, M., Lack, N. A., Zoubeidi, A., Reiter, R. E., Rettig, M. B., Witte, O., Ryan, C. J., Fong, L., Kim, W., Friedlander, T., Chou, J., Li, H., Das, R., Li, H., Moussavi-Baygi, R., Goodarzi, H., Gilbert, L. A., Lara, P. N., Evans, C. P., Goldstein, T. C., Stuart, J. M., Tomlins, S. A., Spratt, D. E., Cheetham, R. K., Cheng, D. T., Farh, K., Gehring, J. S., Hakenberg, J., Liao, A., Febbo, P. G., Shon, J., Sickler, B., Batzoglou, S., Knudsen, K. E., He, H. H., Huang, J., Wyatt, A. W., Dehm, S. M., Ashworth, A., Chinnaiyan, A. M., Maher, C. A., Small, E. J. & Feng, F. Y., Oct 18 2018, In : Cell. 175, 3, 1 p.

Research output: Contribution to journalComment/debate

Genomic Structural Variation
Manuscripts
Amplification
Prostatic Neoplasms
Statistical tests
58 Citations (Scopus)

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., Playdle, D., Barnard, T. J., Zhang, L., Zhang, J., Youngren, J. F., Cieslik, M. P., Parolia, A., Beer, T. T., Thomas, G., Chi, K. N. & 43 others, Gleave, M., Lack, N. A., Zoubeidi, A., Reiter, R. E., Rettig, M. B., Witte, O., Ryan, C. J., Fong, L., Kim, W., Friedlander, T., Chou, J., Li, H., Das, R., Li, H., Moussavi-Baygi, R., Goodarzi, H., Gilbert, L. A., Lara, P. N., Evans, C. P., Goldstein, T. C., Stuart, J. M., Tomlins, S. A., Spratt, D. E., Cheetham, R. K., Cheng, D. T., Farh, K., Gehring, J. S., Hakenberg, J., Liao, A., Febbo, P. G., Shon, J., Sickler, B., Batzoglou, S., Knudsen, K. E., He, H. H., Huang, J., Wyatt, A. W., Dehm, S. M., Ashworth, A., Chinnaiyan, A. M., Maher, C. A., Small, E. J. & Feng, F. Y., Jul 26 2018, In : Cell. 174, 3, p. 758-769.e9

Research output: Contribution to journalArticle

Genomic Structural Variation
Exome
Prostatic Neoplasms
Genes
Androgen Receptors
Oncology
Biopsy
Genes
Tumors
Testing
2 Citations (Scopus)

Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy

Geng, H., Xue, C., Mendonca, J., Sun, X-X., Liu, Q., Reardon, P. N., Chen, Y., Qian, K., Hua, V., Chen, A., Pan, F., Yuan, J., Dang, S., Beer, T. T., Dai, M., Kachhap, S. K. & Qian, Z. D., Dec 1 2018, In : Nature Communications. 9, 1, 4972.

Research output: Contribution to journalArticle

hypoxia
Androgen Receptors
Androgens
therapy
switches
22 Citations (Scopus)

LSD1 activates a lethal prostate cancer gene network independently of its demethylase function

Sehrawat, A., Gao, L., Wang, Y., Bankhead, A., McWeeney, S., King, C. J., Schwartzman, J., Urrutia, J., Bisson, W. H., Coleman, D. J., Joshi, S. K., Kim, D. H., Sampson, D. A., Weinmann, S., Kallakury, B. V. S., Berry, D. L., Haque, R., Van Den Eeden, S. K., Sharma, S., Bearss, J. & 4 others, Beer, T. T., Thomas, G., Heiser, L. & Alumkal, J., May 1 2018, In : Proceedings of the National Academy of Sciences of the United States of America. 115, 18, p. E4179-E4188

Research output: Contribution to journalArticle

Gene Regulatory Networks
Neoplasm Genes
Lysine
Prostatic Neoplasms
Castration
7 Citations (Scopus)

Radiographic progression-free survival as a clinically meaningful end point in metastatic castration-resistant prostate cancer: The PREVAIL randomized clinical trial

Rathkopf, D. E., Beer, T. T., Loriot, Y., Higano, C. S., Armstrong, A. J., Sternberg, C. N., De Bono, J. S., Tombal, B., Parli, T., Bhattacharya, S., Phung, D., Krivoshik, A., Scher, H. I. & Morris, M. J., May 1 2018, In : JAMA oncology. 4, 5, p. 694-701 8 p.

Research output: Contribution to journalArticle

Castration
Disease-Free Survival
Prostatic Neoplasms
Randomized Controlled Trials
Survival

Recycling Discarded Drugs: Improving Access to Oral Antineoplastic Drugs

Layton, J. L., Lewis, B., Ryan, C., Beer, T. T. & Sartor, O., Jan 1 2018, (Accepted/In press) In : Oncologist.

Research output: Contribution to journalArticle

Recycling
Antineoplastic Agents
Pharmaceutical Preparations
2017
54 Citations (Scopus)

Analysis of circulating cell-free DnA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors

Quigley, D., Alumkal, J., Wyatt, A. W., Kothari, V., Foye, A., Lloyd, P., Aggarwal, R., Kim, W., Lu, E., Schwartzman, J., Beja, K., Annala, M., Das, R., Diolaiti, M., Pritchard, C., Thomas, G., Tomlins, S., Knudsen, K., Lord, C. J., Ryan, C. & 5 others, Youngren, J., Beer, T. T., Ashworth, A., Small, E. J. & Feng, F. Y., Sep 1 2017, In : Cancer Discovery. 7, 9, p. 999-1005 7 p.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Recombinational DNA Repair
Mutation
DNA Repair
Biopsy
5 Citations (Scopus)

Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo

Taplin, M. E., Armstrong, A. J., Lin, P., Krivoshik, A., Phung, D., Parli, T., Tombal, B. & Beer, T. T., 2017, (Accepted/In press) In : Journal of Urology.

Research output: Contribution to journalArticle

Castration
Prostate-Specific Antigen
Prostatic Neoplasms
Placebos
Drug Therapy
48 Citations (Scopus)

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer

Wyatt, A. W., Annala, M., Aggarwal, R., Beja, K., Feng, F., Youngren, J., Foye, A., Lloyd, P., Nykter, M., Beer, T. T., Alumkal, J., Thomas, G., Reiter, R. E., Rettig, M. B., Evans, C. P., Gao, A. C., Chi, K. N., Small, E. J. & Gleave, M. E., Dec 1 2017, In : Journal of the National Cancer Institute. 109, 12

Research output: Contribution to journalArticle

Prostatic Neoplasms
Biopsy
DNA
Neoplasms
Castration
27 Citations (Scopus)

Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): A randomised, open-label, international, phase 3 trial

Beer, T. T., Hotte, S. J., Saad, F., Alekseev, B., Matveev, V., Fléchon, A., Gravis, G., Joly, F., Chi, K. N., Malik, Z., Blumenstein, B., Stewart, P. S., Jacobs, C. A. & Fizazi, K., 2017, (Accepted/In press) In : The Lancet Oncology.

Research output: Contribution to journalArticle

docetaxel
Castration
Prednisone
Prostatic Neoplasms
Survival
11 Citations (Scopus)
Androgens
Survivors
Prostatic Neoplasms
Odds Ratio
Therapeutics
5 Citations (Scopus)

Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: An in-depth post hoc analysis of EQ-5D data from the PREVAIL trial

Devlin, N., Herdman, M., Pavesi, M., Phung, D., Naidoo, S., Beer, T. T., Tombal, B., Loriot, Y., Ivanescu, C., Parli, T., Balk, M. & Holmstrom, S., Jun 23 2017, In : Health and Quality of Life Outcomes. 15, 1, 130.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Quality of Life
Placebos
Visual Analog Scale
7 Citations (Scopus)

High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer

Friedlander, T. W., Graff, J., Zejnullahu, K., Anantharaman, A., Zhang, L., Paz, R., Premasekharan, G., Russell, C., Huang, Y., Kim, W., Aggarwal, R. R., Lin, A. M., Fong, L., Alumkal, J., Beer, T. T., Sharifi, N., Alyamani, M., Dittamore, R., Small, E. J., Paris, P. L. & 1 others, Ryan, C. J., 2017, (Accepted/In press) In : Clinical Genitourinary Cancer.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Prostate-Specific Antigen
Therapeutics
Androgens
2 Citations (Scopus)

In reply

Beer, T. T. & Prasad, V., Nov 1 2017, In : JAMA oncology. 3, 11, p. 1588-1589 2 p.

Research output: Contribution to journalLetter

4 Citations (Scopus)

Management of anticoagulation in patients with prostate cancer receiving enzalutamide

Shatzel, J. J., Daughety, M. M., Olson, S. R., Beer, T. T. & Deloughery, T., Nov 1 2017, In : Journal of Oncology Practice. 13, 11, p. 720-727 8 p.

Research output: Contribution to journalReview article

Prostatic Neoplasms
Anticoagulants
Androgen Receptor Antagonists
Castration
Heart Valves

Management of castration-resistant, taxane-resistant prostate cancer

Beer, T. T., Aug 15 2017, In : ONCOLOGY (United States). 31, 8, p. 1-5 5 p.

Research output: Contribution to journalArticle

Castration
docetaxel
Prostatic Neoplasms
Disease Management
Drug Therapy
2 Citations (Scopus)

Management of Castration-Resistant, Taxane-Resistant Prostate Cancer

Beer, T. T., Aug 15 2017, In : Oncology (Williston Park, N.Y.). 31, 8, p. 633-636 4 p.

Research output: Contribution to journalArticle

docetaxel
Castration
Prostatic Neoplasms
Drug Therapy
Radium
185 Citations (Scopus)

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

Gillessen, S., Attard, G., Beer, T. T., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., Daugaard, G., Davis, I. D., de Bono, J., dos Reis, R. B., Drake, C. G., Eeles, R., Efstathiou, E., Evans, C. P., Fanti, S., Feng, F. & 41 others, Fizazi, K., Frydenberg, M., Gleave, M., Halabi, S., Heidenreich, A., Higano, C. S., James, N., Kantoff, P., Kellokumpu-Lehtinen, P. L., Khauli, R. B., Kramer, G., Logothetis, C., Maluf, F., Morgans, A. K., Morris, M. J., Mottet, N., Murthy, V., Oh, W., Ost, P., Padhani, A. R., Parker, C., Pritchard, C. C., Roach, M., Rubin, M. A., Ryan, C., Saad, F., Sartor, O., Scher, H., Sella, A., Shore, N., Smith, M., Soule, H., Sternberg, C. N., Suzuki, H., Sweeney, C., Sydes, M. R., Tannock, I., Tombal, B., Valdagni, R., Wiegel, T. & Omlin, A., 2017, (Accepted/In press) In : European Urology.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Politics
Consensus
Castration
Therapeutics
26 Citations (Scopus)

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer

Armstrong, A. J., Halabi, S., Healy, P., Alumkal, J., Winters, C., Kephart, J., Bitting, R. L., Hobbs, C., Soleau, C. F., Beer, T. T., Slottke, R., Mundy, K., Yu, E. Y. & George, D. J., Aug 1 2017, In : European Journal of Cancer. 81, p. 228-236 9 p.

Research output: Contribution to journalArticle

Castration
Phosphatidylinositol 3-Kinases
docetaxel
Phosphatidylinositol 3-Kinase
Prostatic Neoplasms
6 Citations (Scopus)

Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer

Kim, C. S., Choi, Y. D., Lee, S. E., Lee, H. M., Ueda, T., Yonese, J., Fukagai, T., Chiong, E., Lau, W., Abhyankar, S., Theeuwes, A., Tombal, B., Beer, T. T. & Kimura, G., Jul 1 2017, In : Medicine (United States). 96, 27, e7223.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Placebos
Drug Therapy
Prostate-Specific Antigen
3 Citations (Scopus)

Precision, complexity and stigma in advanced prostate cancer terminology: It is time to move away from 'castration-resistant' prostate cancer

ANZUP Consumer Advisory Panel, Aug 1 2017, In : Annals of Oncology. 28, 8, p. 1692-1694 3 p., mdx312.

Research output: Contribution to journalEditorial

14 Citations (Scopus)

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL

Bryce, A. H., Alumkal, J., Armstrong, A., Higano, C. S., Iversen, P., Sternberg, C. N., Rathkopf, D., Loriot, Y., de Bono, J., Tombal, B., Abhyankar, S., Lin, P., Krivoshik, A., Phung, D. & Beer, T. T., Jan 24 2017, (Accepted/In press) In : Prostate Cancer and Prostatic Diseases.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Disease Progression
Prostatic Diseases
Androgen Receptors
160 Citations (Scopus)

Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer

Beer, T. T., Kwon, E. D., Drake, C. G., Fizazi, K., Logothetis, C., Gravis, G., Ganju, V., Polikoff, J., Saad, F., Humanski, P., Piulats, J. M., Mella, P. G., Ng, S. S., Jaeger, D., Parnis, F. X., Franke, F. A., Puente, J., Carvajal, R., Sengeløv, L., McHenry, M. B. & 3 others, Varma, A., Van Den Eertwegh, A. J. & Gerritsen, W., Jan 1 2017, In : Journal of Clinical Oncology. 35, 1, p. 40-47 8 p.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Placebos
Drug Therapy
Prostate-Specific Antigen
3 Citations (Scopus)

Should Chemotherapy Be Used in Nonmetastatic Prostate Cancer?

Graff, J., Alumkal, J. & Beer, T. T., Jan 1 2017, In : JAMA oncology. 3, 1, p. 11-12 2 p.

Research output: Contribution to journalArticle

Taxoids
Disease-Free Survival
Prostatic Neoplasms
Neoplasm Metastasis
Drug Therapy
14 Citations (Scopus)

Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: Data from PREVAIL and AFFIRM trials

Saad, F., Ivanescu, C., Phung, D., Loriot, Y., Abhyankar, S., Beer, T. T., Tombal, B. & Holmstrom, S., Mar 1 2017, In : Prostate Cancer and Prostatic Diseases. 20, 1, p. 110-116 7 p.

Research output: Contribution to journalArticle

Castration
Spinal Cord Compression
Prostatic Neoplasms
Quality of Life
Confidence Intervals
3 Citations (Scopus)

Taking Care of Our Friends and Neighbors: DeVita's The Death of Cancer and the Challenge of Letting Go

Beer, T. T. & Prasad, V., Jan 1 2017, In : JAMA oncology. 3, 1, p. 16-17 2 p.

Research output: Contribution to journalArticle

Attitude to Death
Terminal Care
Neoplasms
9 Citations (Scopus)

The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies

Beer, T. T., Miller, K., Tombal, B., Cella, D., Phung, D., Holmstrom, S., Ivanescu, C., Skaltsa, K. & Naidoo, S., Dec 1 2017, In : European Journal of Cancer. 87, p. 21-29 9 p.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Quality of Life
Disease-Free Survival
Survival
2016
7 Citations (Scopus)

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor

Coleman, D. J., Van Hook, K., King, C. J., Schwartzman, J., Lisac, R., Urrutia, J., Sehrawat, A., Woodward, J., Wang, N. J., Gulati, R., Thomas, G., Beer, T. T., Gleave, M., Korkola, J., Gao, L., Heiser, L. & Alumkal, J., 2016, In : Oncotarget. 7, 26, p. 40690 1 p.

Research output: Contribution to journalArticle

Androgen Receptors
Androgens
Castration
Prostatic Neoplasms
MDV 3100
11 Citations (Scopus)

CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield

Holmes, M. G., Foss, E., Joseph, G., Foye, A., Beckett, B., Motamedi, D., Youngren, J., Thomas, G., Huang, J., Aggarwal, R., Alumkal, J., Beer, T. T., Small, E. J. & Link, T. M., Dec 19 2016, (Accepted/In press) In : Journal of Vascular and Interventional Radiology.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Biopsy
Bone and Bones
Neoplasms
12 Citations (Scopus)

Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention: Double-blind randomised study of pre-prostatectomy celecoxib or placebo

Flamiatos, J. F., Beer, T. T., Graff, J., Eilers, K. M., Tian, W., Sekhon, H. S. & Garzotto, M., 2016, (Accepted/In press) In : BJU International.

Research output: Contribution to journalArticle

Celecoxib
Chemoprevention
Cyclooxygenase 2
Prostatectomy
Double-Blind Method
7 Citations (Scopus)

Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates

Bergstrom, C. P., Ruffell, B., Ho, C. M. T., Higano, C. S., Ellis, W. J., Garzotto, M., Beer, T. T. & Graff, J., Sep 23 2016, (Accepted/In press) In : Anti-Cancer Drugs.

Research output: Contribution to journalArticle

docetaxel
Mitoxantrone
Prostatectomy
Prostatic Neoplasms
Recurrence
153 Citations (Scopus)

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

Graff, J., Alumkal, J., Drake, C. G., Thomas, G., Redmond, W. L., Farhad, M., Cetnar, J., Ey, F. F., Bergan, R., Slottke, R. & Beer, T. T., Aug 1 2016, In : Oncotarget. 7, 33, p. 52810-52817 8 p.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Cell Death
Castration
Hypothyroidism
Biopsy
6 Citations (Scopus)

Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial

Alumkal, J., Chowdhury, S., Loriot, Y., Sternberg, C. N., de Bono, J. S., Tombal, B., Carles, J., Flaig, T. W., Dorff, T. B., Phung, D., Forer, D., Noonberg, S. B., Mansbach, H., Beer, T. T. & Higano, C. S., Dec 14 2016, (Accepted/In press) In : Clinical Genitourinary Cancer.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Neoplasm Metastasis
Liver
Lung
2 Citations (Scopus)

Effects of ω-3 Fatty Acids and Catechins on Fatty Acid Synthase in the Prostate: A Randomized Controlled Trial

Zhang, Z., Garzotto, M., Beer, T. T., Thuillier, P., Lieberman, S., Mori, M. T., Stoller, W. A., Farris, P. E. & Shannon, J. J., Nov 16 2016, In : Nutrition and Cancer. 68, 8, p. 1309-1319 11 p.

Research output: Contribution to journalArticle

Fatty Acid Synthases
Catechin
Fish Oils
Prostate
Fatty Acids
39 Citations (Scopus)

Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castrationresistant prostate cancer: Results from PREVAIL

Graff, J., Baciarello, G., Armstrong, A. J., Higano, C. S., Iversen, P., Flaig, T. W., Forer, D., Parli, T., Phung, D., Tombal, B., Beer, T. T. & Sternberg, C. N., Feb 1 2016, In : Annals of Oncology. 27, 2, p. 286-294 9 p., mdv542.

Research output: Contribution to journalArticle

Prostatic Neoplasms
Safety
Drug Therapy
Castration
Androgen Receptors
12 Citations (Scopus)

Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial

Kimura, G., Yonese, J., Fukagai, T., Kamba, T., Nishimura, K., Nozawa, M., Mansbach, H., Theeuwes, A., Beer, T. T., Tombal, B. & Ueda, T., May 1 2016, In : International Journal of Urology. 23, 5, p. 395-403 9 p.

Research output: Contribution to journalArticle

Castration
Prostatic Neoplasms
Placebos
Drug Therapy
Prostate-Specific Antigen